Yarrow Bioscience (YARW) Amortization of Deferred Charges (2019)
Yarrow Bioscience's (YARW) quarterly Amortization of Deferred Charges came in at $160000.0 in Q4 2019, down 20.0% quarter-over-quarter from $200000.0 in Q3 2019.
Powered by 
Analysis
Yarrow Bioscience (YARW) Amortization of Deferred Charges (2019) Analysis & Trends
Yarrow Bioscience (YARW) has reported Amortization of Deferred Charges for 1 consecutive years, with $160000.0 the latest figure, recorded in Q4 2019.
- For the quarter ending Q4 2019, Amortization of Deferred Charges changed N/A year-over-year to $160000.0; the trailing twelve-month figure through Dec 2019 stood at $737000.0 (changed N/A YoY), and the FY2019 full-year result was $644000.0, changed N/A from the prior year.
- Amortization of Deferred Charges retreated to $160000.0 in Q4 2019 per YARW's latest filing, from $200000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $200000.0 in Q2 2019 and bottomed at $160000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Yarrow Bioscience | 25.25 Mn | 2.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 160,000.00 |
| Sep 30, 2019 | 200,000.00 |
| Jun 30, 2019 | 200,000.00 |
| Mar 31, 2019 | 177,000.00 |